Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
Among patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.
Authors
- Anssi Solismaa (ORCID: https://orcid.org/0000-0002-0625-711X)
- Ellenor Mittendorfer‐Rutz (ORCID: https://orcid.org/0000-0001-5227-0721)
- Heidi T. Taipale (ORCID: https://orcid.org/0000-0002-3281-934X)
- Jari Tiihonen (ORCID: https://orcid.org/0000-0002-0400-6798)
- Antti O. Tanskanen (ORCID: https://orcid.org/0000-0001-9861-3865)
- Markku Lähteenvuo (ORCID: https://orcid.org/0000-0002-7244-145X)
Institutions
- Tampere University (FI)
- University of Eastern Finland (FI)
- Niuvanniemi Hospital (FI)
- Stockholm County Council (SE)
- Karolinska Institutet (SE)
- Pirkanmaa Hospital District (FI)
Publication Details
- Journal
- JAMA Psychiatry
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1001/jamapsychiatry.2024.3599
- Citations
- 84
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.05